<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEENU- lomustine capsule, gelatin coated </strong><br>E.R. Squibb &amp; Sons, L.L.C.<br></p></div>
<h1>
<span class="Italics">CeeNU</span><span class="Sup">®</span><br>(lomustine)<br>Capsules</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s0"></a><a name="section-1"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">CeeNU
(lomustine) should be administered under the supervision of a qualified physician
experienced in the use of cancer chemotherapeutic agents.</p>
<p>Bone
marrow suppression, notably <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, which may contribute
to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and overwhelming <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in an already compromised patient,
is the most common and severe of the toxic effects of CeeNU (see <span class="Bold"><a href="#s7">WARNINGS</a></span> and <span class="Bold"><a href="#s12">ADVERSE REACTIONS</a></span>).</p>
<p>Since
the major toxicity is delayed bone marrow suppression, blood counts should
be monitored weekly for at least 6 weeks after a dose (see <span class="Bold"><a href="#s12">ADVERSE
REACTIONS</a></span>). At the recommended dosage, courses of CeeNU should
not be given more frequently than every 6 weeks.</p>
<p>The
bone marrow toxicity of CeeNU is cumulative and therefore dosage adjustment
must be considered on the basis of nadir blood counts from prior dose (see <a href="#table1">dosage adjustment table</a> under <span class="Bold"><a href="#s14">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">CeeNU<span class="Sup">®</span> (lomustine)
(CCNU) is one of the nitrosoureas used in the treatment of certain neoplastic
diseases. It is 1-(2-chloro-ethyl)-3-cyclohexyl-1-nitrosourea. It is a yellow
powder with the empirical formula of C<span class="Sub">9</span>H<span class="Sub">16</span>ClN<span class="Sub">3</span>O<span class="Sub">2</span> and
a molecular weight of 233.71. CeeNU is soluble in 10% ethanol (0.05 mg per
mL) and in absolute alcohol (70 mg per mL). CeeNU is relatively insoluble
in water (&lt;0.05 mg per mL).</p>
<p>It is relatively un-ionized
at a physiological pH.</p>
<p>Inactive ingredients in CeeNU
Capsules are magnesium stearate and mannitol.</p>
<p> The
structural formula is: </p>
<div class="Figure"><img alt="Lomustine Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=17893de9-7d54-448c-9fca-d10642046d14&amp;name=ceenu-struct.jpg"></div>
<p>CeeNU is available in
10 mg, 40 mg, and 100 mg capsules for oral administration.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Although it is generally agreed that
CeeNU alkylates DNA and RNA, it is not cross resistant with other alkylators.
As with other nitrosoureas, it may also inhibit several key enzymatic processes
by carbamoylation of amino acids in proteins.</p>
<p>CeeNU
may be given orally. Following oral administration of radioactive CeeNU at
doses ranging from 30 mg/m<span class="Sup">2</span> to 100 mg/m<span class="Sup">2</span>,
about half of the radioactivity given was excreted in the urine in the form
of degradation products within 24 hours.</p>
<p>The serum
half-life of the metabolites ranges from 16 hours to 2 days. Tissue levels
are comparable to plasma levels at 15 minutes after intravenous administration.</p>
<p>Because
of the high lipid solubility and the relative lack of ionization at physiological
pH, CeeNU crosses the blood-brain barrier quite effectively. Levels of radioactivity
in the CSF are 50% or greater than those measured concurrently in plasma. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s5"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">CeeNU has been shown to be useful as
a single agent in addition to other treatment modalities, or in established
combination therapy with other approved chemotherapeutic agents in the following:</p>
<p><span class="Bold">Brain
tumors</span>—both primary and metastatic, in patients who have already received
appropriate surgical and/or radiotherapeutic procedures.</p>
<p><span class="Bold">Hodgkin’s
disease</span>—secondary therapy in combination with other approved drugs
in patients who relapse while being treated with primary therapy, or who fail
to respond to primary therapy. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s6"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">CeeNU should not be given to individuals
who have demonstrated a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Since the major toxicity is delayed bone marrow suppression, blood counts should
be monitored weekly for at least 6 weeks after a dose (see <span class="Bold"><a href="#s12">ADVERSE REACTIONS</a></span>). At the recommended dosage, courses of CeeNU should
not be given more frequently than every 6 weeks.</p>
<p>The bone marrow toxicity of CeeNU is cumulative and therefore dosage adjustment
must be considered on the basis of nadir blood counts from prior dose (see <a href="#table1">dosage adjustment table</a> under <span class="Bold"><a href="#s14">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>Pulmonary toxicity from CeeNU appears to be dose related (see <span class="Bold"><a href="#s12">ADVERSE REACTIONS</a></span>).</p>
<p>Long-term use of nitrosoureas has been reported to be possibly associated with the development of secondary
malignancies.</p>
<p>Liver and renal function tests should be monitored periodically (see <span class="Bold"><a href="#s12">ADVERSE REACTIONS</a></span>).</p>
<div class="Section" data-sectionCode="34077-8">
<a name="s7.1"></a><a name="section-5.1"></a><p></p>
<h2>Pregnancy Category D</h2>
<p class="First">CeeNU can cause fetal harm when administered
to a pregnant woman. CeeNU is embryotoxic and teratogenic in rats and embryotoxic
in rabbits at dose levels equivalent to the human dose. There are no adequate
and well controlled studies in pregnant women. If this drug is used during
pregnancy, or if the patient becomes pregnant while taking (receiving) this
drug, the patient should be apprised of the potential hazard to the fetus.
Women of childbearing potential should be advised to avoid becoming pregnant.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s8"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s8.1"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">In
all instances where the use of CeeNU is considered for chemotherapy, the physician
must evaluate the need and usefulness of the drug against the risks of toxic
effects or adverse reactions. Most such adverse reactions are reversible if
detected early. When such effects or reactions do occur, the drug should be
reduced in dosage or discontinued and appropriate corrective measures should
be taken according to the clinical judgment of the physician. Reinstitution
of CeeNU therapy should be carried out with caution and with adequate consideration
of the further need for the drug and alertness as to possible recurrence of
toxicity.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s8.2"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Provide patients with the following information and instructions:</p>
<ol class="Arabic">
<li>In order to provide the proper dose of CeeNU, the dose may be made up of 2 or more different strengths and colors of capsules. Each strength must be dispensed separately by the pharmacist.</li>
<li>CeeNU is given as a single oral dose and will not be repeated for at least 6 weeks. Daily use of the recommended dose may lead to toxicities and fatal outcomes.</li>
<li>Patients may experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that usually last less than 24 hours. Patients may also experience loss of appetite that may last for several days.</li>
<li>Instruct patients to contact their physician if they develop any of the following reactions: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span>, <span class="product-label-link" type="condition" conceptid="133299" conceptname="Swelling of limb">swelling of feet</span> or lower legs, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, or yellowing of eyes and skin.</li>
<li>Instruct patients to wear impervious (rubber or latex) gloves when handling CeeNU Capsules.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s8.3"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Due to delayed bone marrow suppression,
blood counts should be monitored weekly for at least 6 weeks after a dose.</p>
<p>Baseline
pulmonary function studies should be conducted along with frequent pulmonary
function tests during treatment. Patients with a baseline below 70% of the
predicted Forced <span class="product-label-link" type="condition" conceptid="4147814" conceptname="Vital capacity">Vital Capacity</span> (FVC) or <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">Carbon Monoxide</span> Diffusing Capacity
(DL<span class="Sub">CO</span>) are particularly at risk.</p>
<p>Since
CeeNU may cause liver dysfunction, it is recommended that liver function tests
be monitored periodically.</p>
<p>Renal function tests should
also be monitored periodically.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s8.4"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">CeeNU
is carcinogenic in rats and mice, producing a marked increase in tumor incidence
in doses approximating those employed clinically. Nitrosourea therapy does
have carcinogenic potential in humans (see <span class="Bold"><a href="#s12">ADVERSE
REACTIONS</a></span>). CeeNU also affects fertility in male rats at doses
somewhat higher than the human dose.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s8.5"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s8.5.1"></a><a name="section-6.5.1"></a><p></p>
<h3>Pregnancy Category D</h3>
<p class="First"> See <span class="Bold"><a href="#s7">WARNINGS</a></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8.6"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is
excreted in human milk. Because many drugs are excreted in human milk and
because of the potential for serious adverse reactions in nursing infants
from CeeNU, a decision should be made whether to discontinue nursing or to
discontinue the drug, taking into account the importance of the drug to the
mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8.7"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <span class="Bold"><a href="#s12.2">ADVERSE
REACTIONS: Pulmonary Toxicity</a></span> and <span class="Bold"><a href="#s14">DOSAGE AND ADMINISTRATION</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8.8"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No data from clinical studies of CeeNU
are available for patients 65 years of age and over to determine whether they
respond differently than younger patients. Other reported clinical experience
has not identified differences in responses between elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, reflecting
the greater frequency of decreased hepatic, renal, or cardiac function and
of concomitant disease or other drug therapy.</p>
<p>Lomustine
and its metabolites are known to be substantially excreted by the kidney,
and the risk of toxic reactions to this drug may be greater in patients with
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have
decreased renal function, care should be taken in dose selection, and renal
function should be monitored. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s12"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.1"></a><a name="section-7.1"></a><p></p>
<h2>Hematologic Toxicity</h2>
<p class="First">The most frequent and most serious toxicity
of CeeNU is delayed <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. It usually occurs 4 to 6 weeks after
drug administration and is dose related. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> occurs at about
4 weeks postadministration and persists for 1 to 2 weeks. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> occurs
at 5 to 6 weeks after a dose of CeeNU and persists for 1 to 2 weeks. Approximately
65% of patients receiving 130 mg/m<span class="Sup">2</span> develop white
blood counts below 5000 wbc/mm<span class="Sup">3</span>. Thirty-six percent
developed white blood counts below 3000 wbc/mm<span class="Sup">3</span>.
<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> is generally more severe than <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. However, both may
be dose-limiting toxicities.</p>
<p><span class="Bold">CeeNU may produce
cumulative <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, manifested by more depressed indices or longer
duration of suppression after repeated doses.</span></p>
<p><span class="Bold">The
occurrence of <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span> and <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">bone marrow dysplasias</span> have been reported
in patients following long-term nitrosourea therapy.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>
also occurs, but is less frequent and less severe than <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or
<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.2"></a><a name="section-7.2"></a><p></p>
<h2>Pulmonary Toxicity</h2>
<p class="First">Pulmonary toxicity characterized by pulmonary
infiltrates and/or <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> has been reported rarely with CeeNU. Onset of
toxicity has occurred after an interval of 6 months or longer from the start
of therapy with cumulative doses of CeeNU usually greater than 1100 mg/m<span class="Sup">2</span>.
There is 1 report of pulmonary toxicity at a cumulative dose of only 600 mg.</p>
<p>Delayed
onset <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span> occurring up to 17 years after treatment has been
reported in patients who received related nitrosoureas in childhood and early
adolescence (1–16 years) combined with cranial radiotherapy for intracranial
tumors. There appeared to be some late reduction of pulmonary function of
all long-term survivors. This form of <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">lung fibrosis</span> may be slowly progressive
and has resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in some cases. In this long-term study of carmustine,
all those initially treated at less than 5 years of age died of delayed pulmonary
<span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may occur 3 to 6
hours after an oral dose and usually last less than 24 hours. Prior administration
of antiemetics is effective in diminishing and sometimes preventing this side
effect. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> can also be reduced if CeeNU is administered to
fasting patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.4"></a><a name="section-7.4"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">A reversible type of hepatic toxicity,
manifested by increased transaminase, alkaline phosphatase, and bilirubin levels,
has been reported in a small percentage of patients receiving CeeNU.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.5"></a><a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></h2>
<p class="First">Renal abnormalities consisting of progressive
<span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, decrease in kidney size, and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> have been reported in
patients who received large cumulative doses after prolonged therapy with
CeeNU. Kidney damage has also been reported occasionally in patients receiving
lower total doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.6"></a><a name="section-7.6"></a><p></p>
<h2>Other Toxicities</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>,
and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, such as <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, have been reported infrequently.</p>
<p>Neurological
reactions, such as <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span> have been
noted in some patients receiving CeeNU. However, the relationship to medication
in these patients is unclear. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s13"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with lomustine has been reported, including fatal cases. Accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been associated with bone marrow suppression, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, abnormal hepatic function, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>.</p>
<p>No proven antidotes have been established for CeeNU overdosage. In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, appropriate supportive measures should be taken.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s14"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose of CeeNU in adult
and pediatric patients as a single agent in previously untreated patients
is 130 mg/m<span class="Sup">2</span> as a single oral dose every 6 weeks (see <span class="Bold"><a href="#s8.2">PRECAUTIONS: Information for Patients</a></span> and <span class="Bold"><a href="#s15.2">HOW SUPPLIED: Directions to the Pharmacist</a></span>). In individuals with compromised bone marrow function, the dose should be reduced
to 100 mg/m<span class="Sup">2</span> every 6 weeks. When CeeNU is used
in combination with other myelosuppressive drugs, the doses should be adjusted
accordingly. All doses of CeeNU must be rounded to the nearest 10 mg by the prescriber (see <span class="Bold"><a href="#s15">HOW SUPPLIED</a></span>).</p>
<p>Doses subsequent to the initial dose should
be adjusted according to the hematologic response of the patient to the preceding
dose. The following schedule is suggested as a guide to dosage adjustment:</p>
<a name="table1"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<colgroup>
<col width="33%">
<col width="33%">
<col width="33%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Nadir
After Prior Dose</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><span class="Bold">Percentage
of Prior Dose<br>to be Given</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Leukocytes (/mm<span class="Sup">3</span>)</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">Platelets (/mm<span class="Sup">3</span>)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">≥4000</td>
<td class="Rrule" align="center" valign="middle">≥100,000</td>
<td class="Rrule Toprule" align="center" valign="middle">100%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">3000–3999</td>
<td class="Rrule" align="center" valign="middle">75,000–99,999</td>
<td class="Rrule" align="center" valign="middle">100%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">2000–2999</td>
<td class="Rrule" align="center" valign="middle">25,000–74,999</td>
<td class="Rrule" align="center" valign="middle">70%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">&lt;2000</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">&lt;25,000</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">50%</td>
</tr>
</tbody>
</table>
<p><span class="Bold">A repeat course of CeeNU should not be given until
circulating blood elements have returned to acceptable levels (platelets above
100,000/mm<span class="Sup">3</span>; leukocytes above 4000/mm<span class="Sup">3</span>),
and this is usually in 6 weeks. Adequate number of <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> should
be present on a peripheral blood smear. Blood counts should be monitored weekly
and repeat courses should not be given before 6 weeks because the hematologic
toxicity is delayed and cumulative.</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s15"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">CeeNU<span class="Sup">®</span> (lomustine) Capsules are available in individual bottles of 20 capsules each.</p>
<table border="0" cellpadding="2" cellspacing="1" width="75%">
<colgroup>
<col width="50%">
<col width="50%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td valign="top">
<span class="Bold">NDC</span> 0015-3032-20</td>
<td valign="top">100 mg capsules (Green/Green)</td>
</tr>
<tr>
<td valign="top">
<span class="Bold">NDC</span> 0015-3031-20</td>
<td valign="top">40 mg capsules (White/Green)</td>
</tr>
<tr class="Last">
<td valign="top">
<span class="Bold">NDC</span> 0015-3030-20</td>
<td valign="top">10 mg capsules (White/White)</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="s15.1"></a><a name="section-10.1"></a><p></p>
<h2>Stability</h2>
<p class="First">CeeNU
Capsules are stable for the lot life indicated on package labeling when stored
in well-closed containers at 25°C (77°F); excursions permitted to 15°C–30°C
(59°F–86°F) [see USP Controlled Room Temperature]. Avoid excessive heat (over
40°C, 104°F).</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s15.2"></a><a name="section-10.2"></a><p></p>
<h2>Directions to the Pharmacist</h2>
<p class="First">Confirm the total dose prescribed by the physician can be obtained by determining the appropriate combination
of capsule strengths. Only the appropriate number of CeeNU capsules required for the administration of a single dose should be dispensed.</p>
<p>In order to provide the proper dose of CeeNU, patients should be aware that the prescribed dose may be made up of 2 or more different strengths and colors of capsules and that each strength must be dispensed separately. Inform patients that CeeNU is taken as a single oral dose and will not be repeated for at least 6 weeks. Daily use of the recommended dose may lead to toxicities and fatal outcomes.</p>
<p>Caution should be exercised when handling CeeNU Capsules. Procedures for proper handling and disposal of anticancer
drugs should be utilized. Several guidelines on this subject have been published.<span class="Sup">1-4</span> To minimize the risk of dermal exposure, always wear impervious gloves when handling bottles containing CeeNU Capsules. CeeNU Capsules should not be broken. Personnel should avoid exposure to broken capsules. If contact occurs, wash immediately and thoroughly. More information is available in the references listed below.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s16"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic
and other hazardous drugs in healthcare settings. 2004. U.S. Department of
Health and Human Services, Public Health Service, Centers for Disease Control
and Prevention, National Institute for Occupational Safety and Health, DHHS
(NIOSH) Publication No. 2004-165.</li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling
Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</li>
<li>American Society of Health-System Pharmacists. ASHP guidelines on
handling hazardous drugs. Am J Health-Syst Pharm. 2006;63:1172–1193.</li>
<li>Polovich M, White JM, Kelleher LO, eds. 2005. Chemotherapy and biotherapy
guidelines and recommendations for practice. 2nd ed. Pittsburgh, PA: Oncology
Nursing Society.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br>Bristol-Myers Squibb Company<br>Princeton, NJ 08543 USA<br> Made in Italy<br><br>Rev November 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="PDP1"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">-----------------------------------------<br>REPRESENTATIVE PACKAGING</span></p>
<p>See
<span class="Bold">How Supplied</span> section for a complete list of available packages of CeeNU Capsules.
</p>
<p>
NDC 0015-3032-20<br>20 CAPSULES<br>CeeNU<span class="Sup">®</span> (lomustine) Capsules <br>Rx only<br>100 mg per capsule<br>Caution: DO NOT DISPENSE ENTIRE CONTAINER.<br>Dispense only enough capsules for one dose.</p>
<div class="Figure"><img alt="CeeNU 100 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=17893de9-7d54-448c-9fca-d10642046d14&amp;name=ceenu-100mg-lbl.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="PDP2"></a><a name="section-14"></a><p></p>
<p class="First">
NDC 0015-3031-20<br>20 CAPSULES<br>CeeNU<span class="Sup">®</span> (lomustine) Capsules <br>Rx only<br>40 mg per capsule<br>Caution: DO NOT DISPENSE ENTIRE CONTAINER.<br>Dispense only enough capsules for one dose.</p>
<div class="Figure"><img alt="CeeNU 40 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=17893de9-7d54-448c-9fca-d10642046d14&amp;name=ceenu-40mg-lbl.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="PDP3"></a><a name="section-15"></a><p></p>
<p class="First">
NDC 0015-3030-20<br>20 CAPSULES<br>CeeNU<span class="Sup">®</span> (lomustine) Capsules <br>Rx only<br>10 mg per capsule<br>Caution: DO NOT DISPENSE ENTIRE CONTAINER.<br>Dispense only enough capsules for one dose.</p>
<div class="Figure"><img alt="CeeNU 10 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=17893de9-7d54-448c-9fca-d10642046d14&amp;name=ceenu-10mg-lbl.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEENU 		
					</strong><br><span class="contentTableReg">lomustine capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0015-3032</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>lomustine</strong> (lomustine) </td>
<td class="formItem">lomustine</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Bristol;3032;100;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0015-3032-20</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017588</td>
<td class="formItem">12/15/2008</td>
<td class="formItem">06/30/2014</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEENU 		
					</strong><br><span class="contentTableReg">lomustine capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0015-3031</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>lomustine</strong> (lomustine) </td>
<td class="formItem">lomustine</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN, WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Bristol;3031;40;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0015-3031-20</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017588</td>
<td class="formItem">12/15/2008</td>
<td class="formItem">04/15/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEENU 		
					</strong><br><span class="contentTableReg">lomustine capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0015-3030</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>lomustine</strong> (lomustine) </td>
<td class="formItem">lomustine</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Bristol;3030;10;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0015-3030-20</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017588</td>
<td class="formItem">12/15/2008</td>
<td class="formItem">04/15/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>E.R. Squibb &amp; Sons, L.L.C.
							(968242821)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>41126f73-4e7d-4f0f-bdc1-ff89bbba6fb5</div>
<div>Set id: 17893de9-7d54-448c-9fca-d10642046d14</div>
<div>Version: 8</div>
<div>Effective Time: 20121121</div>
</div>
</div> <div class="DistributorName">E.R. Squibb &amp; Sons, L.L.C.</div></p>
</body></html>
